WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp’s Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
WASHINGTON (Reuters) - A U.S. advisory panel backed Dendreon Corp’s Provenge prostate cancer therapy on Wednesday, telling the Medicare insurance program for the elderly that available data showed it could help patients.
